UroGen Pharma (URGN) Stock Chart & Stock Price History $10.08 -0.63 (-5.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$10.43 +0.35 (+3.43%) As of 02/21/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UroGen Pharma Stock Price Performance 5 Day Performance-6.41%1 Month Performance+0.30%3 Month Performance-15.37%6 Month Performance-30.24%Year-To-Date Performance-5.35%1 Year Performance-43.34% Receive URGN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Stock Chart for Saturday, February, 22, 2025 URGN Chart by TradingView UroGen Pharma Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization02/21/2025$10.71$10.08-5.88%$10.86$10.08801,481 shs$236.38 million02/20/2025$10.82$10.71-1.02%$11.05$10.61214,807 shs$251.15 million02/19/2025$10.56$10.82+2.46%$11.09$10.60218,665 shs$253.73 million02/18/2025$10.77$10.56-1.95%$11.09$10.54206,532 shs$247.63 million02/17/2025$10.77$10.77$10.83$10.49236,525 shs$252.56 million02/14/2025$10.54$10.77+2.18%$10.83$10.49236,525 shs$252.56 million02/13/2025$10.37$10.54+1.64%$10.65$10.38215,472 shs$247.16 million02/12/2025$10.24$10.37+1.27%$10.43$9.86343,012 shs$243.18 million02/11/2025$10.73$10.24-4.57%$10.76$10.16462,524 shs$240.13 million02/10/2025$10.72$10.73+0.09%$10.80$10.52509,382 shs$251.66 million Get the Latest News and Ratings for URGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. 02/07/2025$10.95$10.72-2.10%$10.92$10.58231,947 shs$251.38 million02/06/2025$11.64$10.95-5.93%$11.64$10.91433,734 shs$256.78 million02/05/2025$11.30$11.64+3.01%$11.87$11.29371,827 shs$272.96 million02/04/2025$11.21$11.30+0.80%$11.54$11.08260,041 shs$264.99 million02/03/2025$11.01$11.21+1.82%$11.34$10.77263,138 shs$262.87 million01/31/2025$11.35$11.01-3.00%$11.40$10.84317,963 shs$258.18 million01/30/2025$11.01$11.35+3.09%$11.65$10.98312,628 shs$266.16 million01/29/2025$10.74$11.01+2.51%$11.07$10.53211,571 shs$258.23 million01/28/2025$10.48$10.74+2.48%$10.90$10.25184,152 shs$251.85 million01/27/2025$10.24$10.48+2.34%$10.60$10.21222,984 shs$245.76 million01/24/2025$10.15$10.24+0.89%$10.34$10.00143,649 shs$240.13 million01/23/2025$10.05$10.15+1.00%$10.19$9.85181,309 shs$238.02 million01/22/2025$10.19$10.05-1.37%$10.47$9.88371,876 shs$235.67 million01/21/2025$10.27$10.19-0.78%$10.46$10.00254,851 shs$238.96 million Related Companies AbCellera Biologics Stock Chart Replimune Group Stock Chart Collegium Pharmaceutical Stock Chart Rocket Pharmaceuticals Stock Chart Evolus Stock Chart Pharvaris Stock Chart ArriVent BioPharma Stock Chart Cogent Biosciences Stock Chart Oculis Stock Chart Bicycle Therapeutics Stock Chart Receive URGN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:URGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
